Posaconazole are indicated for use in the treatment of the following fungal infections in patients aged 13 and over:
- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;
Posaconazole indicated for use in the treatment of the following fungal infections in patients aged 18 and over:
- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;
- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;
- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.
Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
Posaconazole are also indicated for prophylaxis of invasive fungal infections in the following patients aged 13 and over:
- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;
- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infection
NOVACTAM is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.
Skin and Skin Structure Infections caused by beta‑lactamase producing strains of Staphylococcus aureus, Escherichia coli,* Klebsiella spp.* (including K. pneumoniae*), Proteus mirabilis,* Bacteroides fragilis,* Enterobacter spp.,* and Acinetobacter calcoaceticus.*
Intra‑Abdominal Infections caused by beta‑lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.*
Gynecological Infections caused by beta‑lactamase producing strains of Escherichia coli,* and Bacteroides spp.* (including B. fragilis*).
* Efficacy for this organism in this organ system was studied in fewer than 10 infections.
While NOVACTAM is indicated only for the conditions listed above, infections caused by ampicillin‑susceptible organisms are also amenable to treatment with NOVACTAM due to its ampicillin content. Therefore, mixed infections caused by ampicillin‑susceptible organisms and beta‑lactamase producing organisms susceptible to NOVACTAM should not require the addition of another antibacterial.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to NOVACTAM.
Type 2 diabetes mellitus
Empagliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
-as monotherapy when metformin is considered inappropriate due to intolerance
-in addition to other medicinal products for the treatment of diabetes
Heart failure
Empagliflozin is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus:
-to reduce the risk of cardiovascular death and hospitalization for heart failure
-to slow kidney function decline
Chronic kidney disease
Empagliflozin is indicated in adults for the treatment of chronic kidney disease.
Antiparkinsonian agent.
Treatment of Parkinson's disease, Zydolev ® frequently is helpful in the management of tremor, dysphagia, sialorrhea and postural instability associated with Parkinson's disease.
Inhibition/suppression of physiological lactation
Cabergoline is indicated for the inhibition of physiological lactation soon after delivery and for suppression of already established lactation:
1. After parturition, when the mother elects not to breast feed the infant or when breastfeeding is contraindicated due to medical reasons related to the mother or the new-born.
2. After stillbirth or abortion.
Cabergoline prevents/suppresses physiological lactation by inhibiting prolactin secretion.
Suppression of milk secretion and relief of breast engorgement and pain are obtained in approximately 85% of nursing women treated with a total dose of 1 mg Cabergoline given in four divided doses over two days. Rebound breast symptomatology after day 10 is uncommon (approximately 2% of cases).
Treatment of hyperprolactinaemic disorders
Cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. Cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations
Gatifloxacin is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
• Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis* Streptococcus pneumoniae
• Aerobic gram-negative bacteria: Haemophilus influenzae
*Efficacy for these organisms were studied in fewer than 10 infections.
Macitentan, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.
Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
First-Line Maintenance Treatment of Advanced Ovarian Cancer
Niraparib is indicated for the maintenance treatment of adult patients with
advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
- Maintenance Treatment of Recurrent Germline BRCA-mutated Ovarian Cancer
Niraparib is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAmut)
recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
A test is used by Your healthcare provider to determine whether you have BRCA mutated ovarian cancer
Renal Tubular Acidosis (RTA) with Calcium Stones
Potassium citrate is indicated for the management of renal tubular acidosis.
Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology
Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis.
Uric Acid Lithiasis with or without Calcium Stones
Potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones.
